JessicaJLinMD

Oncology • Boston, MA

Thoracic Cancer

Thoracic Oncologist

Join to view full profile

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lin's full profile

Already have an account?

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-726-2000

Fax+1 617-726-4803

Summary

Dr. Jessica Lin is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. She received her medical degree from Harvard Medical School and has been in practice for more than 5 years. She also speaks multiple languages, including Korean. She specializes in thoracic oncology and has expertise in clinical and translational research, early drug development, and clinical trials.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2015 - 2018
Brigham and Women's HospitalResidency, Internal Medicine, 2012 - 2015
Harvard Medical SchoolClass of 2012
Harvard UniversityAB

Certifications & Licensure

MA State Medical License 2014 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Start of enrollment: 2015 Nov 19
Active, not recruiting
Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Start of enrollment: 2017 Mar 07
Recruiting
Phase 1, Phase 2
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
Active, not recruiting
Phase 2
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies Start of enrollment: 2019 Jul 30
Terminated
Phase 1
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations Start of enrollment: 2019 Dec 06
Terminated
Phase 1, Phase 2
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Feb 04
Completed
Phase 1
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Start of enrollment: 2020 Sep 29
Active, not recruiting
Phase 2
Immune and Genomic Markers in ALK+ NSCLC Start of enrollment: 2021 Dec 01
Recruiting
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) Start of enrollment: 2022 Jan 04
Recruiting
Phase 1, Phase 2
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC Start of enrollment: 2021 Jul 28
Terminated
Phase 1
Biology of Young Lung Cancer Study: The YOUNG LUNG Study Start of enrollment: 2023 Jan 01
Recruiting
Roles: Principal Investigator
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) Start of enrollment: 2022 Jun 09
Recruiting
Phase 1, Phase 2
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab Start of enrollment: 2019 Oct 21
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

3 citations
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia
Cancer Discovery. 2024-12-02
Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study.
Sai-Hong Ignatius Ou, Benjamin J Solomon, Benjamin Besse, Alessandra Bearz, Chia-Chi Lin
Journal of Thoracic Oncology. 2024-11-22
Advances and future directions in ROS1 fusion-positive lung cancer.
Mary C Boulanger, Jaime L Schneider, Jessica J Lin
The Oncologist. 2024-11-04

Books/Book Chapters

IASLC ATLAS OF MOLECULAR TESTING FOR TARGETED THERAPY IN LUNG CANCER
Chapter: RET
Sanja Dajic, Jessica J Lin, Mauro PapottiEdition 2023,
Cancer Chemotherapy, Immunotherapy and Biotherapy
Chapter: Targeted Therapy in Lung Cancer
Hubbeling HG, Lin JJ, Dagogo-Jack I, Gainor JF, Shaw ATEditors: Chabner BA.Wolters Kluwer HealthEdition 6th,

Abstracts/Posters

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study)
Cho BC, Drilon A, Doebele RC, Kim DW, Lin JJ, Lee J, Ahn MJ, Zhu VW, Camidge R, Stopatschinskaja S, Cui JJ, Hyman DM, Ou SI, Shaw AT, ASCO Annual Meeting 2019, Chicago, IL
Efficacy of platinum-pemetrexed combination chemotherapy in ALK+ non-small cell lung cancer refractory to second-generation ALK TKIs
Lin JJ, Schoenfeld AJ, Zhu VW, Yeap BW, Chin E, Rooney M, Plodkowski AJ, Digumarthy SR, Dagogo-Jack I, Gainor JF, Ou SI, Riely GJ, Shaw AT, ASCO Annual Meeting 2019, Chicago, IL
Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC
Lin JJ, Yeap BY, Ferris LA, Yoda S, Dagogo-Jack I, Lennerz JK, Gainor JF, Shaw AT, ASCO Annual Meeting 2018, Chicago, IL

Lectures

Efficacy of platinum-pemetrexed combination chemotherapy in ALKnon-small cell lung cancer refractory to second-generation ALK TKIs.
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical TrialsDecember 17th, 2024
ROS1 and Lung CancerOctober 2nd, 2024
Dr Lin on the Efficacy and Safety of Taletrectinib in ROS1 Fusion+ NSCLCJuly 2nd, 2024
Join now to see all